Robotic exoskeleton may boost quality of life for MS patients

NCT ID NCT05835622

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers are testing whether wearing a lightweight robotic exoskeleton at home can improve quality of life for people with multiple sclerosis who have walking difficulties. The study includes 28 adults who use a walking aid and live at home. Participants wear the Keeogo exoskeleton for 8 weeks and then have an 8-week period with only advice on physical activity, or vice versa. The main measure is change in quality of life, with walking and balance tests as secondary measures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Keeogo, a lightweight robotic lower limb exoskeleton worn for walking assistance
What this could lead to
If it works, this could offer a home-based tool to help people with multiple sclerosis walk more easily and feel better day to day.
What could go wrong
The trial is small, with 28 participants, and tests one device in a specific group. Results may not apply to others, and the exoskeleton could be uncomfortable or hard to use at home.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 28 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with multiple sclerosis according to the revised Mac Donald diagnostic criteria (2017) in the relapsing-remitting form more than 6 months from a relapsing or progressive period. * An Expanded Disability Status Scale (EDSS) between 5 and 6.5 on the EDSS scale (Kurtzke 1983) * Living at home * Using a walking aid * 18 years old or older * Have freely consented to participate in this study * To be more than 1m52 tall * Hip Manual Muscle Testing (MMT) score ≥ 3+ (flexors and expanders) * Knee Manual Muscle Testing (MMT) score ≥ 2 (flexors and expanders) * Berg scale (BBS) score \> 20 * Patient affiliated with a social security plan or beneficiary of such a plan. Non-Inclusion Criteria: * Impaired comprehension preventing completion of the protocol * Inability to walk without assistance for 10 minutes * Have a rehabilitation stay scheduled during the follow-up period of the clinical investigation * Diagnosed psychiatric conditions that may have an impact on the experience of withdrawal of technical assistance at the end of the protocol * Severe cognitive impairment (MMSE\<24) * Person deprived of liberty by a judicial or administrative decision * A person under psychiatric care or admitted to a health or social institution for purposes other than research. * Spasticity \>3 on the Held and Tardieu scale affecting the hamstring, quadriceps, adductor or sural triceps muscles * Complete paralysis of the lower limbs * Severe osteoporosis * Hip and/or knee replacements that would sufficiently limit range of motion for walking and sitting or squatting * Severe vascular disorders of the lower limbs * Existing wounds or skin lesions where the device is worn * Pregnant woman or postpartum woman who has not completed lumbopelvic recovery * Orthopedic disorders of the lower limb that may prevent satisfactory adjustment of Keeogo * Uncontrolled epilepsy or tremors * Uncontrolled autonomic dysreflexia * Severe balance disorders, neurological disorders (any condition that prevents the safe control of balance and/or movement of the limbs at all times while wearing the Keeogo System) * Conditions that prevent safe moderate-intensity exercise

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU Angers- SSR Les Capucins

    Angers, Pays de la Loire Region, 49103, France

  • CHU Nantes site de Saint Jacques

    Nantes, Pays de la Loire Region, 44093, France

  • Centre de rééducation Fonctionnelle Propara-Montpellier

    Montpellier, Occitanie, 34090, France

  • Hospices Civils de Lyon - Hôpital Henry Gabrielle

    Saint-Genis-Laval, Auvergne-Rhône-Alpes, 69230, France

  • Hôpital Saint Philibert-Groupement des Hôpitaux de l'Institut Catholique de Lille

    Lomme, Hauts-de-France, 59160, France

  • Pôle Saint Hélier

    Rennes, Brittany Region, 35000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.